Skip to main content
Signal8

Immunome Inc. (IMNM)

Sector: Pharmaceutical Preparations

Industry: Biotechnology

Immunome, Inc. logo

Immunome, Inc.

NASDAQ:IMNMHealthcare
+4.50%$18.71
CLOSED
AH$19.48+4.12%vs close
Mkt Cap$2.21B
Float101.21M
O/S118M
VOL1.33M sh
$ Vol$24.64M
RVOL0.85×
Inst Own99.8%
SI17.1%
Dilution
Immunome, Inc. logoNASDAQ:IMNMClosed$18.71+4.50%
Historical Data
DateOpenHighLowCloseVolume
Nov 6, 202618.2118.9617.3218.711,333,752
Nov 5, 202619.3819.4117.2917.912,206,713
Nov 4, 202620.6422.7718.4719.523,461,009
Nov 3, 202619.8120.4319.7820.311,853,938
Nov 2, 202618.4019.7718.4019.592,285,531
Oct 30, 202618.2518.9817.8218.211,271,216
Oct 29, 202618.8819.3018.1118.29877,926
Oct 28, 202618.5018.9118.2518.76952,132
Oct 27, 202617.9519.0017.5018.771,226,156
Oct 26, 202617.9918.3517.7017.89910,529
Oct 23, 202618.1318.2517.6517.991,378,903
Oct 22, 202617.7818.3017.5918.261,761,591
Oct 21, 202617.9918.4417.8518.001,545,127
Oct 20, 202616.7418.2716.5517.922,029,592
Oct 19, 202616.6016.9216.4416.771,139,957
Oct 16, 202617.4017.4016.4116.471,299,733
Oct 15, 202617.3117.6117.0817.401,621,275
Oct 14, 202617.3518.0517.1317.201,155,226
Oct 13, 202619.0619.1617.4317.582,200,215
Oct 12, 202619.4219.7319.0819.15835,816
Analyst Coverage
Analyst Coverage
ConsensusBuy
Price Target
Not available
Ratings Distribution
BUY
13
HOLD
0
SELL
0
TOTAL13
Insider Trades
InsiderTypeShares
Higgins Jack profile photoHiggins JackOption Exercise18.0K
Higgins Jack profile photoHiggins JackOption Exercise18.0K
Higgins Jack profile photoHiggins JackSale13.2K
Higgins Jack profile photoHiggins JackWithholding/Transfer8.8K
Barchas Isaac profile photoBarchas IsaacSale11.0K
Barchas Isaac profile photoBarchas IsaacSale62.3K
Shareholders
99.8%
Institutional
(209)
1.4%
Insiderⓘ
(8)
7.9%
5%+ Owners
(4)
of which 1.2% rests on schedules older than 24 months (1 holder)
-
Unattributed (incl. retail)ⓘ
Institutional99.8%
Insider1.4%
5%+ Beneficial7.9%
Sources: 13F, Form 4, 13D/13GO/S: 118.0M · checked 8 Nov 2026 · market-data provider
Insiders & Institutional Holders

Insiders

Top institutional holders

About

Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States.

The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial.

It is also developing preclinical assets, including IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, such as IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.

Key Metrics
Market Cap$2.21B
Enterprise Value--
P/E Ratio--
Est. Net Cash/Share--
Institutional Ownership99.76%

based on 118.00M shares outstanding

SectorHealthcare
IndustryBiotechnology
ExchangeNASDAQ
CountryUSUS
IPO DateOct 2, 2020
Shares Outstanding118.00M
Authorized Shares
Float101.21M
52-Week Range
$14.64$30.06
$18.71(26th percentile)
Volume
Average Daily Volume1.57M
1.33M today vs 1.57M avg(-15%)

30d Avg

1.57M

60d Avg

1.54M

90d Avg

1.38M

Earnings
Dividend History
No dividend history available
Compliance Status
Loading compliance data...